0000000000148901

AUTHOR

Iris Roth

showing 3 related works from this author

CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack, in human atherosclerotic lesions

1992

Blood cells express a cell membrane protein, termed homologous restriction factor 20 (HRF20) and identical to CD59, that can inhibit complement C5b-9 insertion into their membranes. In this report, we investigated by immunohistochemistry whether CD59 was present on cells in human atherosclerotic lesions since membranous C5b-9(m) has been found in lesions. Using a monoclonal anti-CD59 antibody, a cellular CD59 staining pattern was apparent in nearly all lesion specimens. CD59 stain co-localised with macrophage (CD14), T lymphocyte (CD7), endothelial cell (anti-factor VIII related antigen) and smooth muscle cell cytoskeletal-specific antigens (anti-alpha actin and muscle myosin). Endothelial …

Pathologymedicine.medical_specialtyCell typeArteriosclerosisCD59 Antigenschemical and pharmacologic phenomenaComplement Membrane Attack ComplexMyosinsBiologyAntigenAntigens CDMyosinmedicineHumansMacrophageSaphenous VeinActinComplement Inactivator ProteinsMembrane GlycoproteinsImmunohistochemistryActinsEndothelial stem cellCarotid ArteriesCD59 antigenEndothelium VascularCardiology and Cardiovascular MedicineComplement membrane attack complexAtherosclerosis
researchProduct

The apolipoprotein(a) moiety of lipoprotein(a) interacts with the complement activation fragment iC3b but does not functionally affect C3 activation …

1992

A previous study has shown that complement component C3 binds to recombinant apolipoprotein(a) (r-apo(a)). In the present report we have investigated the interactions between lipoprotein(a) (Lp(a)), r-apo(a) and C3 in relation to complement activation and degradation. Neither Lp(a) nor r-apo(a) affected complement activation as indicated by sheep and rabbit red blood cell hemolytic assays, and by assessment of the amount of C3a generated in zymosan-activated human serum in the presence or absence of Lp(a). Crossed immunoelectrophoretic analyses indicated that Lp(a) retarded the migration of iC3b in complement-activated serum but had no effects on C3, C3b, C3c or C3dg. Recombinant apo(a) exh…

Apolipoprotein BLipoproteinsApoprotein(a)chemistry.chemical_compoundHumansComplement ActivationbiologyComplement C3Lipoprotein(a)N-Acetylneuraminic AcidComplement systemSialic acidApolipoproteinsBiochemistrychemistryLow-density lipoproteinComplement C3bSialic Acidsbiology.proteiniC3bElectrophoresis Polyacrylamide Gellipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineImmunoelectrophoresis Two-DimensionalN-Acetylneuraminic acidLipoprotein(a)LipoproteinAtherosclerosis
researchProduct

Analysis of complement C3 activation products in human atherosclerotic lesions.

1991

Abstract Cleavage of the complement C3 protein is essential for complement activation. Saline extracts of human atherosclerotic lesions were examined by various techniques for the presence of C3 cleavage fragments. Crossed intermediate gel immunoelectrophoresis revealed that native C3 was the predominate C3 protein in extracts and that the C3dg fragment was also detected. SDS-PAGE/ Western blot analyses of lesion extracts employing monoclonal antibodies directed at C3c and C3dg fragment determinants demonstrated molecular weight bands corresponding to the known molecular weights of all the physiologic C3 cleavage fragments, except Cab which is known to have a short half-life. After C3, the …

medicine.diagnostic_testMolecular massArteriosclerosisBlotting WesternEnzyme-Linked Immunosorbent AssayImmunoelectrophoresisArteriesComplement C3BiologyCleavage (embryo)C3-convertasePeptide FragmentsComplement systemBlotBiochemistryWestern blotComplement C3bmedicineHumansLipid particleCardiology and Cardiovascular MedicineComplement ActivationImmunoelectrophoresisAtherosclerosis
researchProduct